114-49-8

应用筛选条件

关键词:'114-49-8'

显示 1-5 共 5 条结果关于 "114-49-8" 范围论文

Alteration of the LRP1B gene region is associated with high grade of urothelial cancer.

Sigrun Langbein et al.

Laboratory investigation; a journal of technical methods and pathology, 82(5), 639-643 (2002-05-11)

We have delineated regions of interest at chromosome 2q21.2, 2q36.3, and 2q37.1 by deletion mapping of 114 urothelial cancers (UC). Altogether, 17%, 18%, and 63% of the G1, G2, and G3 tumors displayed loss of heterozygosity at chromosome 2q, respectively

Carmen E DeMarco et al.

Antimicrobial agents and chemotherapy, 51(9), 3235-3239 (2007-06-20)

Efflux is an important resistance mechanism in Staphylococcus aureus, but its frequency in patients with bacteremia is unknown. Nonreplicate bloodstream isolates were collected over an 8-month period, and MICs of four common efflux pump substrates, with and without the broad-spectrum

Polymorphisms at +49A/G and CT60 sites in the 3' UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism.

R Goswami et al.

International journal of immunogenetics, 32(6), 393-400 (2005-11-30)

Autoimmune diseases such as Graves' disease and type 1 diabetes have been linked with +49A/G and CT60 single nucleotide polymorphisms (SNPs) in the 3' UTR of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene. Both these SNPs are functionally relevant and linked

Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India.

Rama D Mittal et al.

Journal of gastroenterology and hepatology, 22(6), 920-924 (2007-06-15)

Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine associated with inflammatory diseases, while GSTM1 and T1 enzymes catalyze detoxification of products of oxidative stress and hence reduce inflammation. Thus, both may play important roles in the pathogenesis of inflammatory bowel

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Gunter von Minckwitz et al.

The Lancet. Oncology, 15(7), 747-756 (2014-05-06)

Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy

1/1